Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonesupport Holding ABSTU:2B4 +2.21%69 Cyclically Adjusted PB Ratio is 28.31 as of Aug. 09, 2026, which is 3% below its 10-year median of 29.10. GuruFocus rates STU:2B4 with a GF Score™ of 69/100 and a GF Value™ of €38.62 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 520 Medical Devices & Instruments companies, Bonesupport Holding AB ranks worse than 98.85% on this metric.
The historical rank and industry rank for Bonesupport Holding AB's Cyclically Adjusted PB Ratio or its related term are showing as below:
STU:2B4'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 23.08 Med: 29.1 Max: 48.2
Current: 28.47
During the past years, Bonesupport Holding AB's highest Cyclically Adjusted PB Ratio was 48.20. The lowest was 23.08. And the median was 29.10.
STU:2B4's Cyclically Adjusted PB Ratio is ranked worse than 98.85% of 520
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs STU:2B4: 28.47
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Bonesupport Holding AB's adjusted book value per share data for the three months ended in Jun. 2026 was €1.323. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.72 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Bonesupport Holding AB (STU:2B4) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Bonesupport Holding AB Cyclically Adjusted PB Ratio Related Terms
Bonesupport Holding AB Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Bonesupport Holding AB's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonesupport Holding AB Cyclically Adjusted PB Ratio Chart
STU:2B4 vs ISRG, BDX, MDLN: Cyclically Adjusted PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bonesupport Holding AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonesupport Holding AB Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonesupport Holding AB's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Bonesupport Holding AB's Cyclically Adjusted PB Ratio falls into.
Bonesupport Holding AB Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 28.31 mean?
Bonesupport Holding AB (STU:2B4) has a Cyclically Adjusted PB Ratio of 28.31 as of Aug. 09, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Bonesupport Holding AB and its competitors. This is near median its historical median of 29.10. Over the past decade, Bonesupport Holding AB's Cyclically Adjusted PB Ratio has ranged from 23.08 to 48.20. According to the industry distribution chart, Bonesupport Holding AB ranks #514 out of 520 companies in the Medical Devices & Instruments industry, placing it in the top 98.8%.
Is Bonesupport Holding AB's Cyclically Adjusted PB Ratio too high?
Bonesupport Holding AB's current Cyclically Adjusted PB Ratio of 28.31 is near median its 10-year median of 29.10. Over the past 10 years, this metric has ranged from a low of 23.08 to a high of 48.20. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.87. Bonesupport Holding AB's value of 28.31 is 1418% above this industry median. Based on the distribution chart, Bonesupport Holding AB ranks #514 out of 520 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bonesupport Holding AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bonesupport Holding AB's Cyclically Adjusted PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonesupport Holding AB ranks #514 out of 520 companies for Cyclically Adjusted PB Ratio. This places Bonesupport Holding AB in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.87. Bonesupport Holding AB's value of 28.31 is 1418% above this benchmark. Historically, Bonesupport Holding AB's own Cyclically Adjusted PB Ratio has ranged from 23.08 to 48.20 over the past decade. While the company's 10-year median is 29.10 vs. the industry median of 1.87, Bonesupport Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.87, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonesupport Holding AB's current Cyclically Adjusted PB Ratio of 28.31 is 1418% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Bonesupport Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonesupport Holding AB's current Cyclically Adjusted PB Ratio is 28.31, which is near median its own 10-year median of 29.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonesupport Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bonesupport Holding AB (STU:2B4) is currently considered Significantly Undervalued. The stock's GF Value™ is €38.62, compared to a current price of €20.38 — trading 47.2% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 28.31, which is near median its 10-year median of 29.10 and 1418% above the Medical Devices & Instruments industry median of 1.87. Bonesupport Holding AB's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Bonesupport Holding AB (STU:2B4), the current Cyclically Adjusted PB Ratio is 28.31 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonesupport Holding AB (STU:2B4) Overvalued in 2026?
Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued.
The current stock price of €20.38 is trading 47.2% below its estimated GF Value™ of €38.62.
GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.
Key valuation signals for STU:2B4:
Cyclically Adjusted PB Ratio: 28.31 (near median its 10-year median of 29.10)
GF Value™: €38.62 vs. price of €20.38 (47.2% below fair value)
Industry Position: 1418% above the Medical Devices & Instruments median (#514 of 520)
No single metric tells the full story. See the STU:2B4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
69GF Score
Get the complete analysis for STU:2B4
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2B4 has been successfully added to your 
